A simple breath test for tuberculosis using ion mobility : a pilot study

Tuberculosis (TB) remains one of the world's major health burdens with 9.6 million new infections globally. Though considerable progress has been made in reduction of TB incidence and mortality, there is a continuous need for lower cost, simpler and more robust means of diagnosis. One method that may fulfil these requirements is in the area of breath analysis. In this study we analysed the breath of 21 patients with pulmonary or extra-pulmonary TB, recruited from a UK teaching hospital (University Hospital Coventry and Warwickshire) before or within 1 week of commencing treatment for TB. TB diagnosis was confirmed by reference tests (mycobacterial culture), histology or radiology. 19 controls were recruited to calculate specificity; these patients were all interferon-gamma release assay negative (T.SPOT®.TB, Oxford Immunotec Ltd.). Whole breath samples were collected with subsequent chemical analysis undertaken by Ion Mobility Spectrometry. Our results produced a sensitivity of 81% and a specificity of 79% for all cases of TB (pulmonary and extra-pulmonary). Though lower than other studies analysing pulmonary TB alone, we believe that this technique shows promise, and a higher sensitivity could be achieved by further improving our sample capture methodology

Discriminatory ability of gas chromatography-ion mobility spectrometry to identify patients hospitalised with COVID-19 and predict prognosis

Objectives Rapid diagnostic and prognostic tests for COVID-19 are urgently required. We aimed to evaluate the diagnostic and prognostic ability of breath analysis using gas chromatography-ion mobility spectrometry (GC-IMS) in hospitalised patients with COVID-19. Methods Between February and May 2021, we took one breath sample for analysis using GC-IMS from participants who were admitted to hospital for COVID-19, participants who were admitted to hospital for other respiratory infections, and symptom-free controls, at the University Hospitals of Leicester NHS Trust, UK. Demographic, clinical, and radiological data, including requirement for continuous positive airway pressure (CPAP) ventilation as a marker for severe disease in the COVID-19 group, was collected. Results 113 participants were recruited into the study. 72 (64%) were diagnosed with COVID-19; 20 (18%) diagnosed with another respiratory infection, and 21 (19%) healthy controls. Differentiation between participants with COVID-19 and those with other respiratory tract infections with GC-IMS was highly accurate (sensitivity/specificity: 0.80/0.88; [AUROC] 0.85; 95% confidence intervals: CI [0.74-0.96]). GC-IMS was also moderately accurate at identifying those who subsequently required CPAP (sensitivity/specificity 0.62/0.80; [AUROC] 0.70; 95% CI [0.53-0.87]). Conclusions GC-IMS shows promise as both a diagnostic tool and a predictor of prognosis in hospitalised patients with COVID-19 and should be assessed further in larger studies

Early lessons from a second COVID-19 lockdown in Leicester, UK.

Here we report our early experience of the second spike in COVID-19 cases in Leicester. The ethnic pluralism and cultural diversity celebrated by the city now presents complex and considerable public health challenges. As the city enters a local lockdown, we consider whether lessons should be learnt to avoid or better manage similar inevitable surges across other areas of the UK. [Taken from opening paragraph

Data for A simple breath test for Tuberculosis using ion mobility: A pilot study

Tuberculosis (TB) remains one of the world's major health burdens with 9.6 million new infections globally. Though considerable progress has been made in reduction of TB incidence and mortality, there is a continuous need for lower cost, simpler and more robust means of diagnosis. One method that may fulfil these requirements is in the area of breath analysis. In this study we analysed the breath of 21 patients with pulmonary or extra-pulmonary TB, recruited from a UK teaching hospital (University Hospital Coventry and Warwickshire) before or within 1 week of commencing treatment for TB. TB diagnosis was confirmed by reference tests (mycobacterial culture), histology or radiology. 19 controls were recruited to calculate specificity; these patients were all interferon-gamma release assay negative (T.SPOT®.TB, Oxford Immunotec Ltd.). Whole breath samples were collected with subsequent chemical analysis undertaken by Ion Mobility Spectrometry. Our results produced a sensitivity of 81% and a specificity of 79% for all cases of TB (pulmonary and extra-pulmonary). Though lower than other studies analysing pulmonary TB alone, we believe that this technique shows promise, and a higher sensitivity could be achieved by further improving our sample capture methodology